ReviewCurrent atherosclerosis reports2013
Prevention of coronary artery disease: recent advances in the management of hypertension.
Review in Current atherosclerosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Psoriatic arthritis in Africa.Clinical rheumatology · 2021Review
- Associations of the adrenomedullin gene polymorphism with prehypertension and hypertension in Lithuanian children and adolescents: a cross-sectional study.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As coronary artery disease (CAD) still represents the leading cause of death worldwide, more efforts should be made to improve CAD prevention with both lifestyle changes and medical treatment. Elevated blood pressure has been identified as a risk factor for CAD; however, recent evidence suggests that lowering blood pressure too much could be harmful in patients at high cardiovascular risk. Despite the availability of a wide selection of antihypertensive drugs, new strategies and treatments are needed to improve blood pressure control and reduce cardiovascular risk factors associated with elevated blood pressure. New fixed-dose combinations have been recently approved; they usually contain an inhibitor of the renin-angiotensin system, a calcium antagonist and/or a diuretic. Although research and development related to new antihypertensive drugs has slowed in recent years, some new antihypertensive compounds with novel mechanisms of action or dual activity are currently in clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.